NeLM - DermatologyThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the latest items in this publication.

26 records returned

CKS topic review: ChilblainsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: CKS Area: Evidence > Guidelines This Topic Review from the Clinical Knowledge Service (CKS) covers the management of chilblains. (Source: NeLM - Dermatology)
Source: NeLM - Dermatology - November 17, 2009 Category: Dermatology Source Type: organizations

Efracea 40mg Modified Release Capsules (doxycycline) - New formulationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: MIMS Area: Other Library Updates > SPC Changes EFRACEA, a new formulation of doxycycline, is indicated to reduce papulopustular lesions in adult patients with facial rosacea. The daily dose is one 40 mg MR capsule in the morning. (Source: NeLM - Dermatology)
Source: NeLM - Dermatology - November 17, 2009 Category: Dermatology Source Type: organizations

Uncertainties Page: Should we use bath emollients for atopic eczema?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: BMJ Area: News The authors of this article discuss the uncertainties surrounding the use of bath emollients as part of the treatment of atopic eczema, which the NHS in England spent around £15.5m on in 2008. They were unable to identify any published RCTs assessing the clinical efficacy of bath emollients in atopic eczema from a search of the literature. In addition they state that they are not aware of any longstanding clinical experience of benefit from bath emollients to match that for directly applied emollients, and that the quantities of emollient deposited on the skin during bathing ...
Source: NeLM - Dermatology - November 16, 2009 Category: Dermatology Source Type: organizations

Janssen issues letter about reports of toxic epidermal necrolysis and DRESS syndrome associated with etravirine (Intelence®)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: MHRA Area: News In agreement with the EMEA, Janssen has issued a letter to healthcare professionals about cases of toxic epidermal necrolysis (TEN), one of which resulted in fatality and cases of drug rash with eosinophilia and systemic symptoms (DRESS) syndrome associated with the use of etravirine (Intelence®).The time to onset of DRESS syndrome is usually around 3-6 weeks and the outcome in most of the cases is favourable upon discontinuation and after initiation of corticosteroid therapy. Etravirine must be immediately discontinued if severe rash or hypersensitivity reaction is suspected, as a delay in stoppi...
Source: NeLM - Dermatology - November 5, 2009 Category: Dermatology Source Type: organizations

Annual evidence update on psoriasisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: NHS Evidence Area: News NHS Evidence - skin disorders has produced its third annual evidence update on psoriasis, timed to correspond with Psoriasis Awareness Week. The Update includes links to new systematic reviews and guidelines published over the previous year, and a "what's new" analysis discusses the new evidence and its implications for clinical practice. Please see the link below for details. (Source: NeLM - Dermatology)
Source: NeLM - Dermatology - November 2, 2009 Category: Dermatology Source Type: organizations

RCT and cost-effectiveness analysis suggests silver dressings ineffective for venous leg ulcersEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: British Journal of Surgery Area: News According to the results of a prospective randomised trial and cost-effectiveness analysis of silver-donating versus non-silver low-adherence dressings in the treatment of venous leg ulcers there is no evidence to support the routine use of silver-donating dressings beneath compression for venous ulceration. The VULCAN study was a UK multicentre study that randomised 213 patients to silver-donating dressings (n = 107) or non-antimicrobial, low-adherence dressings (n = 106). Dressings were changed at least weekly and were covered by multilayer compression bandaging. ...
Source: NeLM - Dermatology - October 28, 2009 Category: Dermatology Source Type: organizations

Fumaderm®: what is the evidence for its efficacy and safety in psoriasis?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: North West Medicines Information Centre Area: Evidence > Medicines Q & A Fumaderm® (fumaric acid esters) tablets are licensed in Germany for the treatment of adults with moderate to severe plaque psoriasis for whom topical therapy is ineffective. Although unlicensed in the UK and available only through drug import agencies, Fumaderm® is used by specialist dermatology centres. Limited evidence, including only two randomised controlled trials, indicates that Fumaderm® is beneficial in patients with moderate to severe psoriasis, particularly chronic plaque, guttate or pustular disease; at least 50% of patients...
Source: NeLM - Dermatology - October 22, 2009 Category: Dermatology Source Type: organizations

Safety of topical corticosteroids in pregnancyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: Cochrane Library Area: Evidence > Drug Class Focused Reviews Background Topical corticosteroids are the most frequently prescribed dermatological treatment and are frequently used by pregnant women with skin conditions. However, little is known about their safety in pregnancy. Objectives To assess the effects of topical corticosteroids on pregnancy outcomes. Search strategy On 5th May 2009 we searched the Cochrane Skin Group Specialised Register, the Cochrane Pregnancy and Childbirth Group Specialised Register, CENTRAL (The Cochrane Library 2009, Issue 2), MEDLINE (from 2003), and EMBASE (fro...
Source: NeLM - Dermatology - October 14, 2009 Category: Dermatology Source Type: organizations

SMC accepts methotrexate (Metoject®) pre-filled syringes for severe psoriasis and psoriatic arthritisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: Scottish Medicines Consortium (SMC) Area: Evidence > Drug Specific Reviews Following an abbreviated submission, the Scottish Medicines Consortium (SMC) has accepted methotrexate injection 50mg/ml (Metoject®) for use in NHS Scotland for the treatment of severe recalcitrant disabling psoriasis which is not adequately responsive to other forms of therapy (phototherapy, PUVA, and retinoids), and severe psoriatic arthritis in adult patients. The drug advice notes that this is the first licensed parenteral formulation of methotrexate. Please see the link below for further details. (Source: NeLM - Dermatology)
Source: NeLM - Dermatology - October 11, 2009 Category: Dermatology Source Type: organizations

SIGN issues draft guideline on management of atopic eczema in primary careEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: SIGN Area: News The Scottish Intercollegiate Guidelines Network (SIGN) has issued a draft guideline on the management of atopic eczema in primary care for consultation. The guideline provides recommendations for the management of atopic eczema in children and adults in primary care, and includes advice on the various topical treatments for atopic eczema (including moisturisers, topical corticosteroids, topical calcineurin inhibitors and dressings), anti-infective treatments (such as antibiotics and antiseptics), antihistamines, complementary therapies, and the roles of food allergy and environmental fac...
Source: NeLM - Dermatology - September 23, 2009 Category: Dermatology Source Type: organizations

SIGN issues draft guidance on diagnosis and management of psoriasis and psoriatic arthritis in adultsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: SIGN Area: News The Scottish Intercollegiate Guidelines Network (SIGN) has issued a draft guideline on the management of psoriasis and psoriatic arthritis in adults. It covers the early diagnosis of psoriatic arthritis, screening for co-morbidities, assessment of disease severity, non-pharmacological treatment, psychological interventions, topical therapy, phototherapy, systemic therapy, biological treatments, referral pathways and the provision of patient information. The consultation period ends on 31st October 2009. (Source: NeLM - Dermatology)
Source: NeLM - Dermatology - September 23, 2009 Category: Dermatology Source Type: organizations

NICE issues guidance on ustekinumab for the treatment of adults with moderate to severe psoriasisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: NICE Area: Evidence > Guidelines NICE has published guidance (TA 180) recommending ustekinumab as a treatment option for adults with plaque psoriasis when the following criteria are met: . The disease is severe, as defined by a total Psoriasis Area Severity Index (PASI) score of 10 or more and a Dermatology Life Quality Index (DLQI) score of more than 10. . The psoriasis has not responded to standard systemic therapies, including ciclosporin, methotrexate and PUVA, or the person is intolerant of or has a contraindication to these treatments. . The manufacturer provides the 90 mg dose ...
Source: NeLM - Dermatology - September 22, 2009 Category: Dermatology Source Type: organizations

NICE costing template on ustekinumab for the treatment of adults with moderate to severe psoriasisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: NICE Area: News The costing statement accompanying the NICE guidance on ustekinumab for the treatment of adults with moderate to severe psoriasis states that because ustekinumab is one of several biological therapies recommended for the treatment of psoriasis, its implementation is unlikely to result in a significant incremental impact on resources. Commissioners and providers should take account of their local clinical practice when assessing the financial impact. (Source: NeLM - Dermatology)
Source: NeLM - Dermatology - September 22, 2009 Category: Dermatology Source Type: organizations

Humira (adalimumab) Pen and Syringe - Revised SPCEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: eMC (electronic Medicines Compendium) Area: Other Library Updates > SPC Changes In section 4.8 (undesirable effects) the system organ class hepato-biliary disorders in Table 1 has been updated to add very common; elevated liver enzymes. In section 4.8 Table 2 has been updated to add cerebrovascular accident, new onset or worsening of psoriasis (including palmoplantar pustular psoriasis and cardiac disorders) and myocardial infection (Source: NeLM - Dermatology)
Source: NeLM - Dermatology - September 19, 2009 Category: Dermatology Source Type: organizations

Daktacort Hydrocortisone (miconazole / hydrocortisone) Cream - Revised SPCEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: eMC (electronic Medicines Compendium) Area: Other Library Updates > SPC Changes Irritation, skin burning sensation, anaphylactic reaction, contact dermatitis and erythema have been added as undesirable effects in section 4.8. (Source: NeLM - Dermatology)
Source: NeLM - Dermatology - September 19, 2009 Category: Dermatology Source Type: organizations

Locoid C (hydrocortisone butyrate, chlorquinaldol) Cream / Ointment - Product discontinuedEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: eMC (electronic Medicines Compendium) Area: Other Library Updates > SPC Changes Locoid C (hydrocortisone butyrate, chlorquinaldol) Cream and Ointments from Astellas have been discontinued. (Source: NeLM - Dermatology)
Source: NeLM - Dermatology - September 19, 2009 Category: Dermatology Source Type: organizations

Vioform Hydrocortisone (hydrocortisone / clioquinol) Cream and Ointment - Product discontinuedEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: eMC (electronic Medicines Compendium) Area: Other Library Updates > SPC Changes Vioform hydrocortisone (hydrocortisone / clioquinol) cream and ointment from Novartis consumer health have been discontinued. (Source: NeLM - Dermatology)
Source: NeLM - Dermatology - September 19, 2009 Category: Dermatology Source Type: organizations

Elidel (pimecrolimus) 10mg/g cream - Revised SPCEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: eMC (electronic Medicines Compendium) Area: Other Library Updates > SPC Changes Skin papilloma has been added as an uncommon effect to section 4.8 (undesirable effects). (Source: NeLM - Dermatology)
Source: NeLM - Dermatology - September 19, 2009 Category: Dermatology Source Type: organizations

Betesil (betamethasone) 2.250mg Medicated Plaster - New ProductEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: No information given Area: Other Library Updates > SPC Changes Betesil is a new product indicated for the treatment of inflammatory skin disorders which do not respond to treatment with less potent corticosteroids, such as eczema, lichenification, lichen planus, granuloma annulare, palmoplantar pustulosis and mycosis fungoides. Due to its particular pharmaceutical form, BETESIL is suitable for chronic plaque psoriasis localized in difficult to treat areas (e.g. knees, elbows and anterior face of the tibia on an area not greater than 5% of the body surface). (Source: NeLM - Dermatology)
Source: NeLM - Dermatology - September 12, 2009 Category: Dermatology Source Type: organizations

Annual Evidence Update on eczema: 14-18 September 2009Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: NHS Evidence Area: News NHS Evidence - skin disorders is producing its third Annual Evidence Update on atopic eczema on 14 September 2009, with the results of a search for new national guidance and systematic reviews published since the 2008 Annual Evidence Update. (Source: NeLM - Dermatology)
Source: NeLM - Dermatology - September 10, 2009 Category: Dermatology Source Type: organizations

Evidence based treatment recommendations for psoriatic arthritisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: Ann Rheum Dis Area: News Evidence based recommendations on the treatment of various clinical manifestations of psoriatic arthritis (PsA) have been published in the Annals of the Rheumatic Diseases. A systematic review of the literature was conducted on treatment of the most significant discrete clinical manifestations (skin and nails, peripheral arthritis, axial disease, dactylitis and enthesitis) and consensus was sought from rheumatologists, dermatologists and PsA patients. This resulted in the development of 19 treatment recommendations for each of the clinical manifestations and over 80% agreement was obtained...
Source: NeLM - Dermatology - September 9, 2009 Category: Dermatology Source Type: organizations

SMC restricts use of etanercept (EnbrelT) for chronic severe plaque psoriasis in children and adolescentsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: Scottish Medicines Consortium (SMC) Area: Evidence > Drug Specific Reviews The Scottish Medicines Consortium (SMC) has accepted etanercept (EnbrelT) for restricted use within NHS Scotland for the treatment of chronic severe plaque psoriasis in children and adolescents from the age of 8 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. It should be used only when the following criteria are met: . The disease is severe as defined by a total Psoriasis Area Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more...
Source: NeLM - Dermatology - September 7, 2009 Category: Dermatology Source Type: organizations

NICE issues guidance on alitretinoin for the treatment of severe chronic hand eczemaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: NICE Area: Evidence > Guidelines NICE has published guidance on alitretinoin, within its licensed indication, as a treatment option for adults with severe chronic hand eczema that has not responded to potent topical corticosteroids if the person has: . severe disease, as defined by the physician's global assessment (PGA) and . a dermatology life quality index (DLQI) score of 15 or more. Alitretinoin treatment should be stopped: . as soon as an adequate response (hands clear or almost clear) has been achieved or . if the eczema remains severe (as defined by the PGA) at 12 weeks or . if an adequ...
Source: NeLM - Dermatology - August 25, 2009 Category: Dermatology Source Type: organizations

NICE costing template on alitretinoin for the treatment of severe chronic hand eczemaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: NICE Area: News In a costing template on alitretinoin for the treatment of severe chronic hand eczema, NICE estimates the total cost saving of implementing its guidance in England to be £2,989,000 (based on current costs of £83,312,000 and future costs of £80, 323, 000). (Source: NeLM - Dermatology)
Source: NeLM - Dermatology - August 25, 2009 Category: Dermatology Source Type: organizations

Review: mupirocin resistanceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: Clin Infect Dis Area: News A narrative review from the US Centers for Disease Control discusses resistance to mupirocin in view of its increasing use in prophylaxis of MRSA (methicillin-resistant Staphylococcus aureus) infection. The authors discuss the mechanisms and epidemiology of mupirocin resistance, which can be high-level or low-level. These have different mechanisms, and clinical significance: high-level resistance is associated with treatment failure whereas the significance of low-level resistance is uncertain. The rate of resistance is related to level of use, and in at least one case, restri...
Source: NeLM - Dermatology - August 24, 2009 Category: Dermatology Source Type: organizations

NICE issues final appraisal determination on ustekinumab for psoriasisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: NICE Area: News NICE has issued a final appraisal determination on ustekinumab for the treatment of moderate to severe psoriasis in which the preliminary recommendation is that it is a treatment option for adults with plaque psoriasis when the following criteria are met: . The disease is severe, as defined by a total Psoriasis Area Severity Index (PASI) score of 10 or more and a Dermatology Life Quality Index (DLQI) score of more than 10. . The psoriasis has not responded to standard systemic therapies, including ciclosporin, methotrexate and PUVA (psoralen and long-wave ultraviolet...
Source: NeLM - Dermatology - August 13, 2009 Category: Dermatology Source Type: organizations